Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 7Stomach Neoplasms 3Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Esophageal Neoplasms 2Adenocarcinoma 2Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Head and Neck Neoplasms 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced Gastric or EGJ Cancer 1

Interventions

Bevacizumab 57Cetuximab 50Fluorouracil 45Leucovorin 39Oxaliplatin 38pembrolizumab 33Specimen Handling 27Irinotecan 25Magnetic Resonance Spectroscopy 17Biopsy 17Nivolumab 15HMPL-013 13Folfox protocol 13Cisplatin 13Capecitabine 13trifluridine tipiracil drug combination 12Panitumumab 12Gemcitabine 12Carboplatin 12Pemetrexed 10IFL protocol 9encorafenib 8balstilimab 8Standard of Care 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7Trifluridine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Ramucirumab × 90 days × Clear all
NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Novartis

Phase 1 Completed
167 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡